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Environmental exposures to chemically heteroge-
neous endocrine-disrupting chemicals (EDCs) mimic
or interfere with hormone actions and negatively
affect human health. Despite public interest and the
prevalence of EDCs in the environment, methods to
mechanistically classify these diverse chemicals in a
high throughput (HT) manner have not been actively
explored. Here, we describe the use of multiparamet-
ric, HT microscopy-based platforms to examine how
a prototypical EDC, bisphenol A (BPA), and 18 poorly
studiedBPAanalogs (BPXs), affect estrogen receptor
(ER). We show that short exposure to BPA and most
BPXs inducesERaand/or ERb loading toDNAchang-
ing target gene transcription. Many BPXs exhibit
higher affinity for ERb and act as ERb antagonists,
while they act largely as agonists or mixed agonists
and antagonists on ERa. Finally, despite binding to
ERs, some BPXs exhibit lower levels of activity. Our
comprehensive view of BPXs activities allows their
classification and the evaluation of potential harmful
effects. The strategy described here used on a
large-scale basis likely offers a faster, more cost-
effective way to identify safer BPA alternatives.
INTRODUCTION
The impact of environmental endocrine-disrupting chemicals
(EDCs) on human health is widely discussed but remains poorly
understood. By definition, EDCs, usually binding to nuclear
receptors (NRs), act by interfering with any aspect of hormone
action (e.g., synthesis, activity, and degradation), thus altering
hormone-responsive cells and tissues (Zoeller et al., 2012;Myers
et al., 2009). NRs are a large class of transcription factors that
play significant roles in the pathophysiology of virtually every
organ (Nuclear Receptors Nomenclature Committee, 1999).
The steroid receptor subfamily of NRs is the best studied in
the context of EDCs, as it comprises the receptors for estrogens
(ERa and ERb), androgens, progestins, and glucocorticoids. NotChemistry & Biology 21,surprisingly, given widespread environmental exposure, EDCs
have been consistently associated in epidemiological studies
with increased incidence of a number of pathological conditions,
including hormone-dependent cancers (e.g., breast, prostate)
and metabolic (e.g., diabetes and obesity), fertility, neurological,
behavioral (Weiss, 2012), and developmental defects (De Coster
and van Larebeke, 2012; Rochester, 2013). The list of potential
EDCs comprises a large and growing number of individual
compounds or mixtures and their metabolic and environmental
derivatives. These compounds have diverse chemical structures
and are introduced into the environment from both natural and
industrial sources. As suggested by the Environmental Protec-
tion Agency (EPA), existing assays to interrogate known, or iden-
tify new, EDCs use single data points and low-throughput assays
(e.g., in vitro binding and reporter gene assays), even though
recent efforts include high throughput (HT) in vitro assays using
bulk populations of cells (Rotroff et al., 2013). Thus, there is
an urgent need for multiparametric, robust, and HT cell-based
assay platforms that can rigorously investigate the complex
mechanisms underlying the adverse effects of known EDCs
and identify new compounds with endocrine-disrupting poten-
tial. Given the appreciation of cell-to-cell heterogeneity in tumors
and cell cultures, single-cell-based approaches are receiving
increased attention.
Bisphenol A (BPA) is an EDC of concern because of its ability
to induce developmental reprogramming in animal models (Jirtle
and Skinner, 2007; Susiarjo et al., 2013). BPA is in the top 2%
of all high-production-volume chemicals and is frequently used
in the manufacturing of polycarbonate plastics and epoxy
resins. Collectively, there is widespread use of these polymers
in manufacturing of milk and food containers, baby formula
bottles, the interior lining of food cans, paper receipts, and
dental resins (Brotons et al., 1995; Olea et al., 1996), providing
numerous sources for BPA exposure during key periods of
development. BPA has been shown to leach in microgram
amounts from polycarbonate plastics and epoxy resins into
food and water supplies (Welshons et al., 2003), and exposure
to BPA is nearly ubiquitous: urinary analysis reveals that BPA is
detected in >93% of the population of the United States (Calafat
et al., 2005; Calafat et al., 2008).
In part because of these health concerns, many BPA analogs
(BPXs) have been synthesized and are now used as substitutes
for the parent compounds (e.g., bisphenol B [BPB], dimethyl743–753, June 19, 2014 ª2014 Elsevier Ltd All rights reserved 743
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[BPS]). Importantly, there is a paucity of information available
on the effects of these and other BPXs on human health and
the environment, as the vast majority of studies have focused
largely on the parent compounds. When examined, BPXs have
been found to be potentially estrogenic and, in some cases, anti-
androgenic (Kitamura et al., 2005; Rivas et al., 2002; Vin˜as and
Watson, 2013). Thus, large data gaps exist in our understanding
of how these analogs differ from the parent compounds and
whether they present more or less of a hazard to human health.
To interrogate EDC activity and to provide platforms amenable
to HT identification and characterization of potential new EDCs,
we have developed a series of cell-based assay systems that
incorporate multiple facets of ER biology (see Figure 1A for
experimental workflow). These assays and platforms, based on
HT microscopy and multiparametric automated image anal-
ysis, have the ability to characterize EDC activity in the context
of wide-ranging mechanistic depth and with great speed on a
cell-by-cell basis; importantly, these assays are highly comple-
mentary with the ones used in the ToxCast program (Rotroff
et al., 2013). In this study, we have examined 18 BPXs using a
HT multiparametric ‘‘systems-level’’ approach that provides
data over a wide range of characteristics that underlie many
facets of NRs’ mechanisms of action, including DNA- and pro-
tein-based interactions, chromatin remodeling, transcriptional
output, and cell proliferation.
Using these approaches, we found that (1) nearly all BPXs
bound to ERa and/or ERb, suggesting that the development of
BPXs that do not act as ER ligands may be challenging; (2) the
majority of BPXs showed higher affinity for ERb, suggesting
that screens focused exclusively on ERa could underestimate
the effects of potential toxicants; (3) BPXs were predominantly
ERb antagonists but ERamixed agonists; and (4) despite binding
to ERs, some BPXs were inactive or had very low activity at
the highest dose tested across multiple assays, indicating that
ligand binding per se was insufficient to predict BPX activity.
RESULTS
GFP-ERa:PRL-HeLa and GFP-ERb:PRL-HeLa Array Cell
Lines as Sensors of ER DNA Binding, Coregulator
Recruitment, Chromatin Remodeling, and Gene
Transcription
We previously engineered a HeLa-derived cell line with a multi-
copy integration of the estrogen-responsive unit of the prolactin
gene (PRL-HeLa cells; Sharp et al., 2006), which stably ex-
presses GFP-tagged ERa (GFP-ERa:PRL-HeLa; Ashcroft et al.,
2011). This HT-amenable ‘‘big data’’ approach allows direct
visualization and quantification of multiple steps of ER-mediated
transcriptional activation: DNA binding, coregulator recruitment,
large-scale chromatin modeling, and transcription. We previ-
ously used this model system to define and classify the effects
of a small set of estrogenic compounds, including BPA (Ashcroft
et al., 2011).
To complement the ERa-based system, we developed
a similar GFP-tagged ERb stable PRL array cell line (GFP-
ERb:PRL-HeLa), as described in Experimental Procedures. Fig-
ure 1 shows the use of these two cell lines in assays that compare
ERa and ERb activity under agonist (17b-estradiol [E2]) and744 Chemistry & Biology 21, 743–753, June 19, 2014 ª2014 Elsevierantagonist (4-hydroxy-tamoxifen [4OHT]) treatments. First, we
demonstrated that following E2 treatment, the percentage of
cells exhibiting a visible fluorescent signal at the PRL promoter
array increased rapidly (minutes; Figure 1B) and then decayed
over time (hours), as previously described (Ashcroft et al., 2011;
Bolt et al., 2013). Thismeasurement represents ER binding to es-
trogen-responsive element (ERE)-rich promoter/enhancer DNA,
and both ERa and ERb demonstrated similar response kinetics
with E2; as such, the peak time point (30 min) was chosen for
all subsequent experiments. Following these kinetic experi-
ments, a six-point E2 dose-response analysis was performed.
We found that the logarithm of the half maximal effective concen-
tration (EC50) for ERa andERb localization to the arraywas similar
(logEC508.2 versus8.5 M) and within the same range as pre-
viously observed with other in vitro assays (Figure 1C) (Kuiper
et al., 1997). The selective ER modulator (SERM), 4OHT had a
similar logEC50 for ERa and ERb localization to the array, while
the SERM raloxifene showed a preference for ERa over ERb
(logEC50 8.38 versus 7.42 M) (Figures 1D and 1E).
We next evaluated the extent of chromatin remodeling after
array binding by measuring the increase in PRL array area in
response to E2 (Figure 1F). We observed a much larger change
in array size for ERa as compared with ERb, and this difference
was correlated with the extent of mRNA fluorescence in situ
hybridization (FISH) output (see below; Figure 1K). In contrast,
4OHT caused smaller, transcriptionally inactive arrays (Ashcroft
et al., 2011). This suggests that ERa and ERb recruit different
chromatin-remodeling complexes to the PRL array and that
this difference is detectable using these cell lines. We therefore
further investigated the ability of ERa and ERb to recruit the
p160 family of coactivators (SRC-1, SRC-2, and SRC-3) to the
PRL array when liganded with E2 or 4OHT. Coactivator recruit-
ment was determined after 30 min of treatment and measured
as the ratio of array to nucleoplasm intensity (Bolt et al., 2013).
SRC-1 was recruited by both ERa and ERb in response to E2,
with a slight preference for ERa (Figure 1G). SRC-2 was recruited
equally by both ERs (Figure 1H). In contrast, SRC-3 was re-
cruited to the array by only ERa (Figure 1I). As expected, 4OHT
failed to recruit SRC-1, SRC-2, or SRC-3 to the PRL array with
either receptor. Thus, the PRL-HeLa array model uses HTmicro-
scopy to visually detect differences in coregulator recruitment
between ERa and ERb and between agonists (E2) and SERM
(4OHT) ligands, which is similar to previous work by others using
conventional in vitro chromatin immunoprecipitation assays
(Monroe et al., 2003; Wong et al., 2001).
To correlate these observations with ER-mediated changes
in transcription, we measured E2-induced mRNA from the
integrated reporter gene at the PRL array locus (dsRED2) via
mRNA FISH using fluorescently labeled oligonucleotide probes
(Stellaris) (Bolt et al., 2013). To measure immediate changes
in transcription, as opposed to steady-state mRNA levels, we
specifically focused on the 30-min time point after exposure
to compound. Also, as a marker of transcription initiation, we
immunolabeled cells with a monoclonal antibody to serine 5
phosphorylated RNA polymerase II (Figure 1J). The time course
of E2-mediated dsRED2 transcription largely reflected what was
observed for array occupancy (Figures 1B and 1K), with an early
peak between 30 min and 2 hr before plateauing at 50%
maximal activity. Overall, ERa and ERb showed similar kineticsLtd All rights reserved
Figure 1. Comparison of GFP-ERb:PRL-HeLa versus GFP-ERa:PRL-HeLa Stable Cell Lines
(A) Experimental workflow for BPX analysis.
(B) PRL-HeLa array cells (ERa in red and ERb in blue) were treated with 10 nM E2 for the indicated times, and the percentage of cells with an array wasmeasured.
(C–E) Six-point dose-response analysis for the percentage arrays measurement at the 30 min time point for E2 (C), 4-OHT (D), and raloxifene (E).
(F) Six-point dose-response analysis for the array area measurement (in pixels) after 30 min of E2 treatment.
(G–I) Recruitment of SRC-1 (G), SRC-2 (H), and SRC-3 (I) to the array after 30 min of E2 and 4OHT treatment measured as loading (Bolt et al., 2013). *p < 0.05
between ERa and ERb.
(J) Serine 5 phosphorylated RNA polymerase II loading to the array after 30 min of E2 treatment (six-point dose-response analysis).
(K) dsRED2 RNA FISH time-course analysis after E2 treatment represented as intensity at the array normalized to vehicle treatment, which was set as 1.
Error bars represent standard deviation from three to five independent experiments.
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Figure 2. HT Microscopy Platforms Define
ERa versus ERb Selectivity of BPXs
(A) LogEC50 values were calculated after six-point
dose-response analysis using either a PCA or the
PRL array stable cell lines. In the heatmap, red
indicates high-activity compounds, while blue in-
dicates low-activity compounds.
(B–E) Examples of dose-response curves for four
BPXs comparing PCA and PRL array platforms.
Error bars represent standard deviation from three
to five independent experiments.
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ence in magnitude, with ERa eliciting higher levels of activity.
Representative images for some of the data tabulated in Figure 1
are provided in Figure S1 (available online). The similarity in time
course for the peak responses in array loading and gene tran-
scription allowed us to use this early time point (30 min) across
all experiments to compare the effects of BPXs on ERa and ERb.
HTCell-Based Analyses of ERa versus ERb Selectivity of
BPXs Using Protein-Fragment Complementation and
PRL Array Platforms
Next,we further developed a suite of biosensor assays to charac-
terize and quantify ER activity using HT, cell-based, automated
microscopy platforms. The assay systems and experimental
workflow, described in Figure 1A, combined previously validated
protein-fragment complementation assays (PCAs; MacDonald
et al., 2006; Michnick et al., 2006) and the PRL array system
(Ashcroft et al., 2011; Bolt et al., 2013; Sharp et al., 2006).
Engineered nonfluorescent fragments of the N- and C-terminal
portion of the yellow fluorescent protein (YFP) were fused in frame
to sequences encoding the ligand-binding domain (LBD) of ERa
(amino acids 310–547) or ERb (amino acids 263–489) (MacDonald
et al., 2006). Pairs of fusion protein constructs were stably ex-
pressed in humanembryonic kidney293 (HEK293) cells to interro-
gate either ERa or ERb LBD homodimerization upon treatment
with estrogenic compounds. The fluorescent signal generated in
cells is measurable by automated microscopy and image anal-
ysis, as previously described (Figure 2) (MacDonald et al., 2006).
For each assay, changes in mean fluorescence intensity relative
to the E2 control were quantified 8 hr after treatment with the indi-
cated compounds (comparable resultswere obtained after 24 hr).
For the PRL array system, treatment with E2 was for 30min, as
described in Figure 1, and percentage array occupancy was
measured off the GFP-ER channel, as previously described746 Chemistry & Biology 21, 743–753, June 19, 2014 ª2014 Elsevier Ltd All rights reserved(Ashcroft et al., 2011; Bolt et al., 2013).
LogEC50 values were calculated for each
tested compound after performing a
minimum of three independent biological
replicates in a six-point dose-response
analysis (ranging from 100 pM to 10 mM).
After validating the response and quan-
titation strategies of these four cell-by-
cell assays using known ERa and ERb
ligands, we tested 18 BPXs (see Table
S1 for names, chemical structures, and
Chemical Abstracts Service numbers)that are in commercial use; importantly, to date, the potential
endocrine-disrupting activity of these BPXs has been only
partially assessed. As shown in Figure 2A, we determined the
relative binding affinity of each BPX for ERa and ERb in com-
parison with E2, 4OHT, or raloxifene using PCA assays and
determined array occupancy of liganded ERa and ERb using
PRL arrays.
In Figure 2A, BPXs’ logEC50 values across all four HT assays
are presented in heatmap fashion, where red represents high
and blue low activity on the assays. Figures S2 and S3 show
full dose-response profiles for PRL array recruitment and the
EC50 values. For most BPXs, ER binding and dimerization by
PCA and array occupancy were similar, although differences
were observed between ERa and ERb. One of the most
interesting observations from this initial analysis was a clear
selectivity of multiple BPXs for ERb compared to ERa (Figures
2B–2E). Some BPXs that are notable for their difference in po-
tency between the two ERs include bisphenol C (BPC), bisphe-
nol AF (BPAF), BPB, and bisphenol Z (BPZ). An example of a
compound with a unique profile is BPS, a BPX that has recently
been proposed as a possible substitute for BPA; however, it
appears to disrupt E2 nongenomic activities (Vin˜as and Watson,
2013). BPS was unable to induce ERa binding to PRL arrays,
very little ERa dimerization, and, relative to other BPXs, exhibited
only low levels of activity as a ligand for ERb.
Interestingly, the ability of BPXs to induce ER dimerization did
not necessarily correlate with PRL array occupancy, indicating
that dimerization was not sufficient to induce DNA binding.
BPF, MH-BPF, TM BPA, and MH-MM1 were able to induce
receptor dimerization in the PCA assay at doses that were not
cytotoxic while being largely unable to induce DNA binding to
the ERE-rich PRL arrays.
The ability of BPXs to maximally induce receptor binding to
DNA and chromatin remodeling relative to estrogen treatment
Figure 3. Analysis of Efficacy and Chromatin-Remodeling Potential of BPXs
Percentage of cells with an array (A) or array area (B) was measured at the maximal BPX dose (10 mM) after 30 min of treatment of GFP-ERa:PRL-HeLa and GFP-
ERb:PRL-HeLa cells. Heatmaps were generated after normalizing the data to E2, which was set as 1. Error bars represent standard deviation from three to five
independent experiments.
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for 30 min (Figure 3A). Using this measure, most BPXs are
capable of inducing ER binding to the PRL array to a degree
equal to or better than E2 in the ERb-containing cells, whereas
a more heterogeneous response was observed with ERa. In
ERa-containing cells, for example, some BPXs (MH-MM1, TM
BPA) were capable of causing array formation in 50% of the
cells, while none showed higher response than E2. In ERb-con-
taining cells, on the other hand, the maximal tested dose of
many BPXs caused greater responses than E2 (BPA, BPC,
BPAF, bisphenol AP [BPAP], MM2, dimethyl[dimethylbutyli-
dene] [DMDMB] BPA, dimethylbutylidene [DMB] BPA, BPZ,
BPB), while only few had an intermediate response (50% of
E2; BPS, MH-MM1).
As shown in Figure 3B, we were able to observe and quan-
tify differences in the area of the PRL arrays elicited by the
different agents, a reflection of large-scale chromatin remodel-
ing. A general observation was that even for BPXs capable of
forming arrays, the changes in array area were significantly
smaller than when cells were treated with E2, and larger than
with 4OHT, implicating an intermediate phenotype of BPXsChemistry & Biology 21,between classic agonists and antagonists. This was particu-
larly evident in ERa-containing cells, for which the PRL arrays
are much larger in size after E2 treatment (see Figure 1F). How-
ever, in most cases, the same trend was observed in ERb-con-
taining cells, even though the size of the array is much smaller.
These observations highlight the likely differential use of chro-
matin-remodeling complexes by ERa and ERb and the rela-
tive importance of conformational changes that some BPXs
can elicit on ERb versus ERa. Further, these results also
demonstrate the utility of these multiparametric assay formats
for dissecting differences between closely related chemical
structures.
As shown in Figure 1K, the dsRED2 reporter linked to the pro-
lactin promoter/enhancer regulatory unit allows the PRL array
system to simultaneously measure transcriptional responses
using mRNA FISH. ERa- or ERb-expressing PRL-HeLa cells
were treated with BPXs at a maximal dose of 10 mM, alone (Fig-
ure 4A) or in combination with 10 nM E2 for 30 min (Figure 4B).
Following this short E2 treatment, de novo mRNA production
increased 4- to 8-fold in the ERa-containing cells and 2- to
4-fold in the ERb-containing cells. 4OHT had very little agonist743–753, June 19, 2014 ª2014 Elsevier Ltd All rights reserved 747
Figure 4. Transcriptional Response to
BPXs in PRL Array Cell Lines
(A and B) dsRED2 RNA FISH intensity at the array
after 30 min of BPX 10 mM (A) or BPX + E2 10 nM
(B) in GFP-ERa:PRL-HeLa (gray bars) or GFP-
ERb:PRL-HeLa (black bars) cells. Veh = vehicle.
Error bars represent standard deviation from 3
independent experiments.
(C and D) Venn diagrams representing the
different categories of responses by BPXs in
ERa-containing (C) or ERb-containing (D) cells.
See text for further description of the categories.
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and for this reason, it was used as the control antagonist in
these experiments.
Following data mining of ERa-containing cells, BPXs could be
divided into roughly four groups on the basis of transcriptional
activity (Figure 4C): (1) largely inactive (<2-fold over vehicle or
<50% reduction of E2 activity, e.g., BPF), (2) partial agonists
or antagonists (>2-fold over vehicle and >50% reversal of E2,
e.g., BPZ), (3) agonists (>2-fold over vehicle but no reversal of
E2 activity, e.g., BPA), and (4) antagonists (<2-fold over vehicle
and >50% reduction of E2, e.g., 4OHT; no BPX was a complete
antagonist). From the RNA FISH analysis, it is clear that on ERa,
some BPXs are largely transcriptionally inactive even at 10 mM
(32%); however, a bigger group showed either agonist or partial
agonist or antagonist activity (68%).
ERb-containing PRL array cells revealed a distinctly different
picture, with only two classes of responses being evident (Fig-
ure 4D). The BPXs were either inactive (42%, e.g., MH-BPF) or
antagonistic (58%, e.g., BPAF). None of the compounds tested
in the ERb cell model led to mRNA accumulation at the dsRED2
transcriptional reporter gene locus. A very interesting observa-
tion was that most of the BPXs appeared to antagonize E2 acti-
vation of ERb, even though they were categorized as agonist or
mixed agonist and antagonist in ERa-containing cells. Future
studies will address the structural basis of this phenomenon
and determine if it occurs also in vivo.748 Chemistry & Biology 21, 743–753, June 19, 2014 ª2014 Elsevier Ltd All rights reservedEffect of BPXs on ERa Activity in
MCF-7 Breast Cancer Cells
To evaluate the effect of BPXs on endog-
enous ER protein levels, we treatedMCF-
7 breast cancer cells either with BPXs
alone (10 mM) or with BPXs plus E2
(10 nM) for 24 hr. We used immunofluo-
rescence to quantify the nuclear level
of ERa protein (Figure 5A) throughout
the population of cells. As expected,
following 24 hr of treatment, E2 caused
a 40% to 50% reduction of ERa, which
is comparable with previous observations
by us and others (Borra´s et al., 1996).
As shown in Figure 5A, a few BPXs
reduced ERa levels to a degree similar
to E2 (e.g., BPB, MM2, MonoMxy), while
most showed little activity and none
showed a 4OHT-like profile. In combina-tion studies with E2, only one of the BPXs (DMB BPA) showed
partial antagonism.
In order to test the effect of BPXs on endogenous ER
target gene expression, we optimized an HT, low-magnification
(203), mRNA FISH protocol for GREB1, a well-characterized
and highly E2-induciblemRNA.We used a set of specific fluores-
cently labeled oligonucleotides that recognize GREB1 introns to
identify active transcriptional loci in the nucleus (Raj and Tyagi,
2010) (see Figure S4 for representative images). This strategy
allowed us to count the transcriptional active foci in a fast, accu-
rate, and reproducible way. We treated MCF-7 cells with 10 nM
E2 for 24 hr, a time point that was chosen to guarantee maximal
E2-mediated induction of GREB1 mRNA in MCF-7 cells, thus
expanding the dynamic range of response.
Quantitative mRNA FISH reveals an E2-dependent increase in
GREB1 transcriptional bursting from less than 0.5 foci per cell to
over 1.5 foci per cell (Figure 5B). Because there are four copies of
the GREB1 gene in MCF-7 cells (Kocanova et al., 2010), we saw
a distribution of responses to E2 ranging from cells that have all
four copies active to cells that do not show any transcriptional
bursting.
We then treated MCF-7 cells with BPXs alone or with E2 for
24 hr and measured the average number of GREB1 transcrip-
tional foci per cell (Figure 5B). Using this analysis, most BPXs
showed no or little activity when treated alone. However, some
(e.g., DM DMB BPA, BPB, BPA) showed an increase in the
Figure 5. Effect of BPXs on Endogenous ERa Activity in MCF-7 Breast Cancer Cells
(A) MCF-7 cells were treated for 24 hr with BPXs (10 mM, gray bars) or BPX + E2 10 nM (black bars) and then labeled with ERa antibody. Nuclear ER intensity was
then quantified. Data are represented as relative to vehicle control.
(B) MCF-7 cells were treated for 24 hr with BPXs (10 mM, gray bars) or BPX+E2 10 nM (black bars) and then hybridized with GREB1 intron mRNA FISH probes.
Data indicate the average number of transcriptionally active foci per cell after setting vehicle treatment at 1.
Error bars represent standard deviation from three independent experiments.
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BPZ, BPC) were capable of almost completely abrogating the
agonistic effects of E2.
As a means of comparison between our HT data and more
traditional assays used to measure EDC activity, we used a
well-established MCF-7 cell proliferation assay (Soto et al.,
1995). In brief, MCF-7 cells were treated with vehicle, 1 nM
E2, or BPXs in a six-point dose-response analysis for 6 days.
The effect of each BPX relative to 1 nM E2 was calculated using
two metrics (Table 1): the relative proliferative effect (RPE),
which represents the ratio between the highest cell number
achieved with a given BPX and E2 (3100), and the relative
proliferative potency (RPP), which is the ratio between the min-
imum E2 concentration needed for maximal cell number and the
minimal BPX concentration needed to achieve the same cell
density.
In this proliferation assay, most BPXs showed an RPE >
70% (14 of 19), indicating their ability to induce cell prolif-
eration similarly to E2. Interestingly, two BPXs (BPAP and
tetrabromobisphenol A [TBBPA]) never reached a cell num-
ber similar to E2, indicating their lack of proliferative ability.
Despite the ability of most BPXs to induce MCF-7 cell prolifer-
ation, their RPP was significantly lower than E2, similar to pre-
vious studies (Rivas et al., 2002). The most active in this assay
was DM DMB BPA, which had 0.033% activity compared
with E2.Chemistry & Biology 21,Clustering Analysis of BPX Activity across All HT
Microscopy Assays
In order to generate a more comprehensive view of BPXs’ activ-
ity, we compiled all the data (Figures 1, 2, 3, 4, and 5; Table 1) into
a cluster dendrogram (Figure 6). We first standardized the data
from each experiment, including SRC-3 recruitment to the PRL
array in ERa-containing cells (no ERb data were included for
this parameter because no recruitment of SRC-3 was measured
after E2 treatment; see Figure 1I and Figure S1), by range
normalization, and then we clustered them using Euclidean dis-
tance. Clusters highlight the fact that E2 and SERM treatments
stand alone, indicating that none of the BPXs display pure estro-
gen- or SERM-like activity across all the assays performed.
However, BPXs were divided into two major clusters: (1) a
minimally active subset (BPF, MH-BPF, tetrachlorobisphenol
A, TBBPA, and BPS) and (2) a BPA-centric group. Each of the
BPX clusters can be further subdivided into smaller branches
that highlight specific functional and mechanistic differences.
From the hierarchal clustering dendrogram, it is interesting to
note that the assays are largely divided into three branches.
In the first branch, the assays designed for dimerization and tran-
scriptional complex formation (PCA and PRL array mRNA FISH)
cluster together and also with endogenous ER nuclear levels
in MCF-7 cells. The second branch contains mostly functional
and mechanistic measurements (e.g., array area, coregulator
binding, efficacy in array formation). Last, the third branch is743–753, June 19, 2014 ª2014 Elsevier Ltd All rights reserved 749
Table 1. BPXs’ Effects on MCF-7 Cell Proliferation
Compound RPE (%)a RPP (%)b
E2 100 100
DMDMB BPA 91.93 0.033
BPC 77.97 0.0105










TM BPA 30.34 0.000316
BPS 97.54 0.000105
MonoMxy BPA 77.15 0.000033
TC BPA 142.21 0.0000316
BPAP c c
TB BPA c c
Raloxifene c c
aThe RPE is the ratio of the highest cell yield with compound to the
highest cell yield with E2.
bThe RPP is the ratio of the number of minutes (E2) needed for maximal
cell yield to the number of minutes (compound) needed to achieve similar
effect.
cMaximal cell density is not reached at any dose.
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tion. Another interesting observation from the assay dendrogram
is that there is no separation between ERa and ERb assays; how-
ever, the biggest distance between the two receptors occurs at
the level of RNA FISH output, when E2 is combined with BPXs
and with the mechanistic endpoints (array area and efficacy in
percentage arrays).
We alsowanted to compare our assay platformswith chemical
structure similarities in terms of classifying BPXs. In order to do
this, we calculated the Tanimoto distance between all the BPXs,
4OHT, and E2 and generated a cluster diagram on the basis of
their relative structural similarities (Figure S5). By both hierarchi-
cal clustering and multidimensional scaling, it is clear that the
BPXs are different from both E2 and 4OHT, as is also evident
from the clustering analysis shown in Figure 6. From this anal-
ysis, it appears that the simple chemical structural analysis
does not perfectly overlap with the estrogenic activity as deter-
mined by our multiple assays. This further highlights the rele-
vance of our multiple-endpoint mechanistic platforms to better
characterize EDCs’ activity, which could be additive to more
traditional structure-activity relationship analyses currently
based on available data sets.
DISCUSSION
The number of chemicals that are synthesized and dispersed in
the environment has grown exponentially in recent years. It is750 Chemistry & Biology 21, 743–753, June 19, 2014 ª2014 Elseviernow evident that many of them can have serious impacts on
the environment and on human health. However, with the
increasing synthesis of new chemical compounds, there is a
need for improved HT platforms to query and classify their
effects as broadly as possible. One example of molecules with
effects on human health is EDCs. These affect mostly the endo-
crine system, altering basic physiological functions such as
development, reproduction, and metabolism. They do so by
interfering with many aspects of hormonal regulation, which
include acting as ligands for NRs, key sensors of hormonal and
environmental stimuli. The best studied EDC is BPA, whose
widespread use in many common products has led to its detec-
tion in over 80% to 90% of individuals living in developed coun-
tries (Rochester, 2013; Rubin, 2011). BPA levels have been
linked to numerous developmental and reproductive defects in
animal models (Rubin, 2011). For these reasons, plastic manu-
facturers have developed series of BPA derivatives (BPXs) at
least in part to circumvent problemswith BPA; however, rigorous
and appropriate testing remains to be performed. The hope for
some of these compounds would be to reduce the environ-
mental and negative health footprint. Many of the BPXs are
already used in the manufacturing of polycarbonate plastics
and epoxy resins. In some cases, a series of analytical
approaches have been attempted, but they have not provided
a deep understanding of their mechanism of action (Kitamura
et al., 2005). A comprehensive analysis of these compounds is
highly desirable, as it will enable an understanding of structure-
function relationships that may facilitate the rapid identification
of potential EDCs and help drive the manufacture and commer-
cial use of nontoxic alternatives.
In recent years, the EPA and the National Institute of Environ-
mental Health Sciences (NIEHS) have started specific programs
for the analysis of potentially toxic compounds, which include
EDCs (e.g., ToxCast and Tox21). The assays used in these pro-
grams are very robust and allow the determination of a com-
pound as a potential EDC. Although these efforts are essential,
ToxCast assays do not frequently query mechanistic aspects
of these compounds, which become more important when
series of analogs are synthesized.
Here, we developed a series of multiple-endpoint, micro-
scopy-based, HT platforms and queried the effects of 18 BPXs
on ERa and ERb. These platforms have many advantages over
more classic approaches (i.e., reporter gene assays) in that
they readily offer a cost-effective, multiparametric, mechanistic
view of test compounds on a cell-by-cell basis that permits
classification and identification of specific differences. Because
these platforms are amenable to HT analysis of known or poten-
tially bioactive compounds that can directly bind to NRs or
compete with endogenous hormones, they will help generate a
complete cartography of EDCs. From this study, we obtained
several important insights on BPXs and identified some future di-
rections that will be needed to fully generate a complete analysis
of EDC action.
One interesting observation was that most BPXs (but not all)
were capable of binding one or both ERs, generally with higher
affinity for ERb, a largely understudied receptor in EDC charac-
terization. Moreover, BPXs acted mostly as ERb antagonists in
our model system, while they acted largely as agonists or mixed
agonists and antagonists on ERa. Interestingly, despite beingLtd All rights reserved
Figure 6. Clustering Analysis of BPXs’
Activity across All HT Microscopy Assays
Performed
Data in each assay row were range normalized
before clustering analysis. Clustering was per-
formed using Euclidean distance for both the
compounds and the assays.
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some functional endpoint assays (e.g., gene transcription, cell
proliferation), indicating the importance of querying multiple pa-
rameters for each compound in order to more precisely classify
their activity. A recognized limitation of our study is the lack of a
stable and reliable in vitro model system to test the effect of
BPXs on endogenous ERb, hampering our ability to extend the
observations obtained with our engineered ERb model. Specif-
ically, high-quality imaging-compatible ERb antibodies are being
developed toward this goal.
This study also highlights the need for adding additional as-
says to query other important NRs and transcription factors
that have the potential to bind EDCs (e.g., aryl hydrocarbon
receptor, liver X receptor, estrogen-related receptors, peroxi-
some proliferator-activated receptor g). We are moving toward
this goal by generating multiple PCA assays that cover all NRs
and by adapting the PRL array system to other NRs by the
use of chimeric receptors (e.g., NRs with an ER DNA binding
domain swapped in). The development of such tools will allow
us to broaden the spectrum of assays for the characterization
of EDCs and their metabolites and mixtures. When evaluating
potential EDCs, it is important to keep in mind the impossibility
of covering all possible mechanisms of EDC action in one (or
few) assays. For instance, although our HT platforms assess
numerous mechanistic steps of EDC activities, they do yet
not address hormone-induced nongenomic actions, hormone
synthesis, metabolism, and so on (Watson et al., 2014; Marino
et al., 2012). For this reason, an inactive EDC by our assays
does not guarantee complete inactivity in other cell culture
or animal model systems or in the context of environmental
exposure. However, the platforms used in this study could
definitely increase knowledge of EDC actions and are highlyChemistry & Biology 21, 743–753, June 19, 2014complementary with the assays in the
ToxCast and Tox21 programs.
In conclusion, at a technical level, the
use of multiparametric, HT microscopy-
based platforms provides a remarkably
complete view of EDC activity compared
with existing technologies and can be
performed in a fast, quantitative, and
cost effective fashion. Furthermore, the
mechanistic data arising from these
studies clearly indicate the need to more
thoroughly understand EDCs’ effects on
a much wider swath of gene regulators
than, as has been the case for years,
primarily being concerned with effects
on ERa. Last, the use of such platforms
on a larger scale basis should provide amuch improved determination of (for example) plasticizers that
are less likely to be biologically active.
SIGNIFICANCE
EDCs are a very large class of chemical structures that
impinge on human health at multiple levels (e.g., develop-
ment, reproduction, metabolism). Many of these com-
pounds act through their direct binding to NRs, which
include the ERs. One of themost studied EDCs is BPA,which
is produced and used as plasticizer in many day-to-day
products. Because of the wealth of data on its impact on
human health and the environment, many BPXs have been
synthesized as potential substitutes. These compounds
and their effects have not been well studied. In this study,
we developed a series of multiparametric, microscopy-
based assays to generate a fine map of BPXs’ activity on
ERa and ERb. We identified several important characteris-
tics of BPXs: most are capable of binding to either receptor,
weak to strong activities were identified, and many act as
antagonists on ERb, a previously unappreciated mechanism
of action. In conclusion, our study highlights the importance
for a thorough analysis and classification of putative EDCs
across contextual assay platforms to directly assess and
classify the activity of chemicals on NRs.
EXPERIMENTAL PROCEDURES
Cell Lines, Cell Culture Conditions, and Materials
The GFP-ERb:PRL-HeLa cell line was created by stably expressing full-length
GFP-ERb in PRL-HeLa parental cells (Sharp et al., 2006) using a blasticidin
resistance gene. The cells are grown in phenol red-free Dulbecco’s modified
Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS; Geminiª2014 Elsevier Ltd All rights reserved 751
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HT Functional Classification of BPA AnalogsBioproducts), L-glutamine, sodium pyruvate, 0.8 mg/ml blasticidin, 200 mg/ml
hygromycin, and 10 nM raloxifene (Sigma). The GFP-ERa:PRL-HeLa cells
are grown in the same medium, with 10 nM 4OHT substituted for raloxifene.
Cells were grown in treatment media (phenol red-free DMEM containing 5%
stripped/dialyzed FBS, L-glutamine, and sodium pyruvate and no drugs) for
at least 48 hr prior to treatment. MCF-7 cells were grown in phenol red-free
DMEM containing 10% FBS, L-glutamine, and sodium pyruvate. Cells were
robotically seeded using a Titertek dispenser in 384-well glass-bottom plates
(Greiner Bio-one) precoated with 5% charcoal stripped and dialyzed FBS for a
minimum of 4 hr.
BPXs were obtained from Sigma or Santa Cruz Biotechnology and solubi-
lized in DMSO. Estrogen, raloxifene, and 4OHT (Sigma) were solubilized in
ethanol.
PCA Assays
The ERa/a LBD and ERb/b LBD stable cell lines were generated by cotrans-
fecting fusion constructs encoding the LBD of ERa (amino acids 310–547) or
ERb (amino acids 263–489) fused to fragment 1 or fragment 2 of the Venus
variant of YFP into HEK93T cells, as previously described (MacDonald et al.,
2006; Yu et al., 2003). The cells are grown in phenol red-free DMEM contain-
ing 10% FBS, L-glutamine, sodium pyruvate, and 200 mg/ml Zeocin (Life
Technologies). Cells were seeded into 384-well poly-D-lysine-coated plates
(Perkin Elmer) in treatment media (phenol red-free DMEM containing 5%
charcoal stripped and dialyzed FBS, L-glutamine, and sodium pyruvate)
for 24 to 48 hr prior to drug treatment using a MultiDrop cell dispenser. Cells
were treated with agent (in final DMSO concentration of 0.5%) in triplicate
wells for 8 hr, fixed with 4% formaldehyde, and stained with Draq5 to
identify cells. Fluorescence data in the 488 nm (YFP) and 635 nm (Draq5)
channels were collected on the Acumen eX3 laser scanning cytometer
(TTP Labtech). For each well, the average PCA fluorescence intensity for
all cells is normalized by the total nuclear area (normalized total intensity).
Each data point for each experiment represents the average of three wells.
LogEC50 values for each experiment were derived by normalizing each data
point to the max E2 value on each plate (100 nM). Data presented in all fig-
ures represent the average logEC50 value from at least three independent
experiments, and all error bars represent the SEM across the independent
experiments.
Cell Proliferation Assay
MCF-7 cells were maintained as described above. Forty-eight hours prior to
drug treatment, cells were seeded into 384-well poly-D-lysine-coated plates
in treatment media. Cells were treated with vehicle, E2, or drug for 6 days,
as described for the E-Screen assay developed to identify estrogenic com-
pounds (Soto et al., 1995), and the number of viable cells was assessed using
Alamar Blue staining (Life Technologies). The RPP and RPE of each test com-
pound were calculated as previously described (Soto et al., 1995).
RNA FISH
RNA FISH experiments were completed as previously described (Bolt et al.,
2013). Cells were fixed in 4% purified formaldehyde (Electron Microscopy Sci-
ences) in ribonuclease (RNase)-free PBS for 15 min and then permeabilized
with 70% ethanol in RNase-free water at 4C for 1 hr. Cells were washed in
1 ml of wash buffer (2 3 saline sodium citrate [SSC] [Ambion] plus 10% form-
amide) followed by 4 hr of 37C hybridization with mRNA FISH probes
(dsRED2 or GREB1 Stellaris probes; Biosearch Technologies) in buffer (1 g
dextran sulfate, 1 ml 20 3 SSC buffer, 1 ml formamide, and 8 ml nuclease-
free water) followed by one wash in wash buffer for 30 min at 37C, then fol-
lowed by DNA staining with 40,6-diamidino-2-phenylindole (DAPI) for 10 min at
37C. Finally, cells were washed in 2 3 SSC buffer and imaged.
Immunofluorescence
Immunofluorescence experiments were completed as previously described
(Bolt et al., 2013). Briefly, cells were fixed in 4% formaldehyde in PEM buffer
(80 mM potassium PIPES [pH 6.8], 5 mM EGTA, and 2 mM MgCl2), quenched
with 0.1 M ammonium chloride for 10 min, and permeabilized with 0.5%
Triton X-100 for 30 min. Cells were incubated at room temperature in blotto
(5% milk in 1 3 Tris-buffered saline/Tween 20) for 1 hr, and then specific
antibodies were added overnight at 4C prior to 30 min of secondary antibody752 Chemistry & Biology 21, 743–753, June 19, 2014 ª2014 Elsevier(Alexa conjugates; Molecular Probes) and DAPI staining (1 mg/ml for 1 min).
The primary antibodies used were mouse anti-Ser5-phospho RNA poly-
merase II (Abcam, ab5401), mouse anti-SRC-1 (BD Transduction Labs No.
612378), mouse anti-SRC-2 (BD Transduction Labs No. 610985), mouse
anti-SRC-3 (BD Transduction Labs No. 611105), and rabbit anti-ERa
(Millipore 04-820).
HT Microscopy and Image Analysis
Automated imaging was carried out using the IC-200 HT microscope (Vala
Sciences). Dual-step high-speed (50–100 ms) reflection- and image-based
autofocused image fields were acquired with a sCMOS 5.5 megapixel camera
through a Nikon S Fluor 40 3 /0.90 NA objective. Z-stacks were imaged
at 1 mm intervals at 1 3 1 binning. Nuclear array segmentation and signal
quantification were performed using PipelinePilot image analysis software
(Accelrys) as previously described (Ashcroft et al., 2011; Bolt et al., 2013).
Aggregated cells, mitotic cells, and apoptotic cells were removed using filters
based on nuclear size, nuclear shape, and nuclear intensity.
Statistical Analysis
Every experiment was standardized on the basis of estrogenic activity (E = U
Umin/Umax  Umin). Heatmaps were generated using the Matrix2png pro-
gram; clustering was performed using Cluster 3.0 and visualized with Java
Treeview; Tanimoto distance andMDS plots were calculated using ChemMine
tools (Backman et al., 2011; de Hoon et al., 2004; Saldanha, 2004; Pavlidis and
Noble, 2003). GraphPad Prism 5.0 was used to construct graphs and dose-
response curves, calculate EC50, perform t tests, and so on. Every experiment
was repeated between three and six independent times. In the 384-well plate
experiments, every condition was tested in quadruplicate.
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